The initial offering amount is for $115M and will be used to advance the development of trilaciclib, G1T38, G1T48 for treatment of breast cancer and small cell lung cancer (Filing, S-1, G1 Therapeutics, APR 13, 2017, View Source [SID1234518582]).

The stock will trade on the Nasdaq with symbol "GTHX."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!